{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:18:12Z","timestamp":1771870692754,"version":"3.50.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.3816\/clml.2010.n.069","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T23:44:49Z","timestamp":1289432689000},"page":"361-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia"],"prefix":"10.3816","volume":"10","author":[{"given":"Susan","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.069_bib1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ctrv.2007.08.003","article-title":"Recent progress in the management of chronic lymphocytic leukemia","volume":"33","author":"Robak","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CLML.2010.n.069_bib2","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"Ca Cancer J Clin"},{"key":"10.3816\/CLML.2010.n.069_bib3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia: prognostic significance","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.069_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib5","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib6","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/10428190701882955","article-title":"Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications","volume":"49","author":"Zenz","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.069_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF03256292","article-title":"Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia","volume":"12","author":"Higgins","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"10.3816\/CLML.2010.n.069_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2008.07012.x","article-title":"Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients","volume":"141","author":"Tam","year":"2008","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.069_bib10","author":"National Cancer Institute"},{"key":"10.3816\/CLML.2010.n.069_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2165\/00003495-200161050-00005","article-title":"Achieving optimal outcomes in chronic lymphocytic leukaemia","volume":"61","author":"Hamblin","year":"2001","journal-title":"Drugs"},{"key":"10.3816\/CLML.2010.n.069_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2043.2043","article-title":"Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international Phase III study","volume":"110","author":"Knauf","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib14","author":"National Comprehensive Cancer Network"},{"key":"10.3816\/CLML.2010.n.069_bib15","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib16","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3816\/CLM.2002.n.008","article-title":"Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia","volume":"3","author":"Schmitt","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLML.2010.n.069_bib18","first-page":"1662","article-title":"Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"91","author":"Brugiatelli","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.069_bib19","first-page":"1641","article-title":"What is the optimal initial treatment for chronic lymphocytic leukemia?","volume":"21","author":"Lin","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.3816\/CLML.2010.n.069_bib20","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib21","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib22","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","article-title":"Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables","volume":"26","author":"Anderson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib23","first-page":"65","article-title":"Management of advanced chronic lymphocytic leukemia","volume":"2","author":"Cao","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"10.3816\/CLML.2010.n.069_bib24","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.069_bib25","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/10428190701573257","article-title":"The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy","volume":"48","author":"Tam","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.069_bib26","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/cncr.0680","article-title":"Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population","volume":"94","author":"Perkins","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.069_bib27","author":"National Cancer Institute"},{"key":"10.3816\/CLML.2010.n.069_bib28","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib29","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.beha.2007.03.005","article-title":"Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia","volume":"20","author":"Grever","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.3816\/CLML.2010.n.069_bib31","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.069_bib32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CLML.2010.n.069_bib34","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.seminoncol.2006.01.027","article-title":"Strategies in the management of alemtuzumab-related side effects","volume":"33","author":"Osterborg","year":"2006","journal-title":"Semin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.069_bib36","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/leu.2009.146","article-title":"Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia","volume":"23","author":"Osterborg","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.069_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.3816\/CLML.2010.n.069_bib38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.3816\/CLML.2010.n.069_bib39","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.3816\/CLML.2010.n.069_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains","volume":"7","author":"Einfeld","year":"1988","journal-title":"EMBO J"},{"key":"10.3816\/CLML.2010.n.069_bib41","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.4049\/jimmunol.139.10.3521","article-title":"Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity","volume":"139","author":"Liu","year":"1987","journal-title":"J Immunol"},{"key":"10.3816\/CLML.2010.n.069_bib42","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1365-2141.2003.04305.x","article-title":"Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells","volume":"121","author":"Sieber","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.069_bib43","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib44","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.4049\/jimmunol.177.10.7435","article-title":"Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia","volume":"177","author":"Williams","year":"2006","journal-title":"J Immunol"},{"key":"10.3816\/CLML.2010.n.069_bib45","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1046\/j.1365-2141.2003.04683.x","article-title":"Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease","volume":"123","author":"Giles","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.069_bib46","first-page":"177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.3816\/CLML.2010.n.069_bib47","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib48","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.3816\/CLML.2010.n.069_bib49","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2008-04-149161","article-title":"Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation","volume":"112","author":"Beers","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/1096-8652(200008)64:4<275::AID-AJH7>3.0.CO;2-Y","article-title":"Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders","volume":"64","author":"D'Arena","year":"2000","journal-title":"Am J Hematol"},{"key":"10.3816\/CLML.2010.n.069_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cyto.b.20359","article-title":"Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia","volume":"72","author":"Rossmann","year":"2007","journal-title":"Cytometry B Clin Cytom"},{"key":"10.3816\/CLML.2010.n.069_bib52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.seminhematol.2008.02.007","article-title":"Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma","volume":"45","author":"Martin","year":"2008","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.069_bib53","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib54","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib55","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group","volume":"79","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"key":"10.3816\/CLML.2010.n.069_bib57","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib58","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0609.2002.02786.x","article-title":"Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study","volume":"69","author":"Itala","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.069_bib60","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib61","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.critrevonc.2007.04.008","article-title":"Chronic lymphocytic leukemia","volume":"64","author":"Ghia","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.3816\/CLML.2010.n.069_bib63","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib64","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib67","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib68","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib70","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","article-title":"Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies","volume":"101","author":"Faderl","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib71","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/10428190412331286096","article-title":"A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and\/or refractory chronic lymphocytic leukemia (CLL)","volume":"45","author":"Nabhan","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"suppl 3","key":"10.3816\/CLML.2010.n.069_bib72","first-page":"9.8","article-title":"Long term results of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for patients with relapsed and refractory chronic lymphocytic leukemia","volume":"94","author":"Frankfurt","year":"2009","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.069_bib73","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V112.11.325.325","volume":"112","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib74","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood.V114.22.535.535","volume":"114","author":"Hallek","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib75","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.3816\/CLML.2010.n.069_bib76","first-page":"10.32","article-title":"Long term results of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for patients with relapsed and refractory chronic lymphocytic leukemia","volume":"94","author":"Badoux","year":"2009","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.069_bib77","article-title":"FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"106","author":"O'Brien","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib78","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"10.3816\/CLML.2010.n.069_bib79","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.069_bib80","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.069_bib81","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/156800908783769319","article-title":"Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia","volume":"8","author":"Robak","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"10.3816\/CLML.2010.n.069_bib82","author":"US National Institutes of Health"},{"key":"10.3816\/CLML.2010.n.069_bib83","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib84","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4049\/jimmunol.181.1.822","article-title":"Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis","volume":"181","author":"Beum","year":"2008","journal-title":"J Immunol"},{"key":"10.3816\/CLML.2010.n.069_bib85","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood.V112.11.1578.1578","article-title":"Binding of submaximal C1q to B cells opsonized with anti-CD20 mabs ofatumumab (OFA) or rituximab (RTX) promotes complement dependent cytotoxicity (CDC), and considerably higher levels of CDC are induced by OFA than by RTX","volume":"112","author":"Taylor","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib86","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1\u20132 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.069_bib87","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.069_bib88","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.207.207","article-title":"Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial","volume":"114","author":"Wierda","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011702026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011702026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:02Z","timestamp":1761870242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011702026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S2152265011702026"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.069","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}